- Home
- EXAS vs DT Comparison
EXAS vs DT Comparison
Compare EXAS & DT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- DT
- Stock Information
- Founded
- EXAS 1995
- DT 2005
- Country
- EXAS United States
- DT United States
- Employees
- EXAS N/A
- DT N/A
- Industry
- EXAS Medical Specialities
- DT Computer Software: Prepackaged Software
- Sector
- EXAS Health Care
- DT Technology
- Exchange
- EXAS Nasdaq
- DT Nasdaq
- Market Cap
- EXAS 12.3B
- DT 13.2B
- IPO Year
- EXAS N/A
- DT 2019
- Fundamental
- Price
- EXAS $49.33
- DT $52.35
- Analyst Decision
- EXAS Strong Buy
- DT Buy
- Analyst Count
- EXAS 17
- DT 25
- Target Price
- EXAS $73.07
- DT $60.50
- AVG Volume (30 Days)
- EXAS 3.3M
- DT 2.9M
- Earning Date
- EXAS 11-05-2024
- DT 11-07-2024
- Dividend Yield
- EXAS N/A
- DT N/A
- EPS Growth
- EXAS N/A
- DT N/A
- EPS
- EXAS N/A
- DT 0.54
- Revenue
- EXAS $2,692,328,000.00
- DT $1,563,293,000.00
- Revenue This Year
- EXAS $12.41
- DT $20.03
- Revenue Next Year
- EXAS $11.64
- DT $15.61
- P/E Ratio
- EXAS N/A
- DT $96.97
- Revenue Growth
- EXAS 11.91
- DT 20.58
- 52 Week Low
- EXAS $40.62
- DT $39.42
- 52 Week High
- EXAS $79.62
- DT $61.41
- Technical
- Relative Strength Index (RSI)
- EXAS 22.62
- DT 42.36
- Support Level
- EXAS $48.02
- DT $53.02
- Resistance Level
- EXAS $52.32
- DT $54.42
- Average True Range (ATR)
- EXAS 2.86
- DT 1.57
- MACD
- EXAS -1.89
- DT -0.28
- Stochastic Oscillator
- EXAS 5.28
- DT 6.23
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening.
About DT Dynatrace Inc.
Dynatrace is a cloud-native company that focuses on analyzing machine data. Its product portfolio, delivered as software as a service, allows a client to monitor and analyze its entire IT infrastructure. Dynatrace's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to use it for a variety of applications throughout their businesses.